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Abstract. 1 
Objectives: To evaluate emtricitabine (FTC) pharmacokinetics (PK) in pregnant women and 2 
their neonates and to determine the optimal prophylactic dose for neonates after birth to 3 
prevent mother-to-child transmission of HIV (PMTCT). 4 
Methods: 38 HIV-infected pregnant women were administered Tenofovir Disoproxyl 5 
Fumarate (TDF, 300mg)- emtricitabine (FTC, 200mg) tablets: 2 at the initiation of labour and 6 
1 daily for 7 days postpartum. By pair, 11 maternal, 1 cord blood and 2 neonatal FTC 7 
concentrations were measured using an HPLC MS MS validated method and analyzed by a 8 
population approach.  9 
Results: Model and mean estimates (inter-patient variability) were a 2-compartment model for 10 
mother with absorption rate constant 0.54 h-1 (61%), apparent elimination and 11 
intercompartmental clearance 23.2 (17%) and 6.04 L.h-1 and apparent central and peripheral 12 
volume 127 and 237L; an effect compartment linked to maternal circulation for cord and a 13 
neonatal compartment disconnected, after delivery, with a 10.6 hours half life (30%). After 14 
the 400 mg FTC administration, median population AUC, Cmax and Cmin in pregnant women 15 
were 14.3 mg.L-1.h, 1.68 and 0.076 mg/L respectively. At delivery, median (range) FTC 16 
predicted maternal and cord concentrations were respectively 1.16 (0.14–1.99) and 0.72 17 
(0.05–1.19) mg.L-1.   18 
Conclusion: The 400 mg FTC administration in pregnant women produces higher exposition 19 
than the 200 mg administration to adults, at steady state. FTC was shown to have good 20 
placental transfer (80%). Administering FTC 1 mg/kg as soon as possible after birth or 2 21 
mg/kg 12 hours after birth should produce neonatal concentrations comparable to those 22 
observed in adults.  23 
Introduction 24 
To prevent mother-to-child transmission of HIV around the delivery, a single-dose 25 
administration of nevirapine (sdNVP) administered at start of labour is the most common 26 
antiretroviral regimen used in resource-limited settings, as recommended by the World Health 27 
Organization in the antiretroviral drugs for treating pregnant women and preventing HIV 28 
infection in infants report (http://www.who.int/hiv/pub/guidelines/pmtctguidelines3.pdf). 29 
However, the use of sdNVP results in resistance mutations in 15 to 70% of women, at 4 to 6 30 
weeks postpartum, compromising the success of subsequent treatments with NVP in mother 31 
and child (7, 9). A recent clinical study suggests that adding a single dose of TDF and FTC at 32 
delivery may reduce those resistances by half (6).  33 
Emtricitabine is a potent, once daily (QD) nucleoside reverse transcriptase inhibitor approved 34 
for the treatment of human immunodeficiency virus (HIV) in adults and children older than 3 35 
months in combination with other antiretroviral agents. The physiological changes associated 36 
with pregnancy can lead to significant variations in pharmacokinetics (10, 12, 14). However, 37 
few pharmacokinetic data on emtricitabine in pregnant women (3) and no data on placental 38 
transfer are available. Only one study reports pharmacokinetic of emtricitabine in neonates 39 
exposed to HIV in utero; apparent elimination clearance was 13 mL/min in 5 to 21 days-old 40 
neonates and 22 mL/min in 23 to 42 days-old neonates (5). This suggests that the youngest 41 
neonates have the lowest elimination clearance. The neonatal pharmacokinetics just after birth 42 
is still unknown.  43 
In the present work, a population pharmacokinetic study was performed on mother, cord and 44 
neonatal plasma samples in order i) to describe the concentration-time courses of FTC in 45 
mothers, the transfer of FTC from maternal plasma to cord plasma and the neonatal 46 
elimination, ii) to study the influence of covariates (such maternal bodyweight, gestational 47 
age, type of delivery, maternal creatinine, neonatal bodyweight, height and body surface area) 48 
on FTC pharmacokinetics and iii) to model various dosing strategies to determine optimal 49 
dosing scheme for newborn. 50 
 51 
Methods 52 
 53 
Patients. 54 
The TEmAA (Tenofovir/Emtricitabine in Africa and Asia) - ANRS 12-109 study was an 55 
open, phase I/II trial evaluating the pharmacokinetics, the safety and toxicity of the 56 
Tenofovir-Emtricitabine combination in HIV infected pregnant women and their neonates. 57 
This trial was conducted in Abidjan, Côte d’Ivoire, Phnom Penh, Cambodia and Soweto, 58 
South Africa. Pregnant women (between 28 and 38 weeks of gestation), older than 18 years, 59 
infected by HIV-1 or HIV-2, naïve to all antiretroviral treatment, who had an indication for 60 
antiretroviral prophylaxis for Prevention of Mother-To-Child-Transmission (PMTCT) during 61 
pregnancy (in line with international or national recommendations: WHO’s clinical stage 1, 2 62 
and CD4≥200/mm3 or stage 3 and CD4≥350/mm3) were eligible. Neonates with a gestational 63 
age greater than 32 weeks and a birth weight greater than 2000 grams were eligible. This 64 
study protocol was approved by the national ethics committees of Côte d’Ivoire, South Africa 65 
and Cambodia and by each country health authorities. The mother and the father of the child 66 
to be born provided signed informed-consent.  67 
 68 
Treatments 69 
Mothers were administered ZDV (300 mg twice a day) from enrolment to delivery date, one 70 
tablet of NVP (200 mg) and two tablets of TDF (300 mg)-FTC (200 mg) at start of labour, 71 
and one tablet of TDF (300 mg)-FTC (200 mg) per day during 7 days at postpartum. Children 72 
were given NVP syrup (2 mg/kg) as a single-dose on the first day of life and ZDV syrup (4 73 
mg/kg every 12 hours during 7 days).  74 
 75 
Sampling 76 
All women received FTC and underwent blood samplings for pharmacokinetic analysis: at 77 
delivery, 1, 2, 3, 5, 8, 12 and 24 hours after the administration of FTC 400 mg and before the 78 
2nd , 3rd and 7th administration of FTC 200 mg. A cord blood sample was obtained at delivery, 79 
the neonate had sampling on days 1 and 2 of life. Time elapsed between administrations and 80 
sampling time, maternal, fetal bodyweight and gestational age were recorded. 81 
 82 
Analytical method   83 
The emtricitabine essay was performed according to the previously published method (11) 84 
with a limit of quantification (LOQ), intra- and inter-assay precision of 0.01 mg/L, 3.6 % and 85 
7.9 %. The biais between observed and theoretical concentration range from 0.7 to 14.9 %.    86 
 87 
 Modeling strategy and population pharmacokinetic model. 88 
Data were analyzed using the nonlinear mixed effect modeling software program NONMEM 89 
(version VI, level 1.0) with the DIGITAL FORTRAN compiler (2). The first-order 90 
conditional estimation (FOCE) with interaction method was used. A 2-compartment model 91 
with first order absorption and elimination best described maternal data. For cord 92 
concentrations, an “effect” compartment model of negligible volume and negligible drug 93 
accumulation linked to the maternal circulation was used. The effect compartment is modeled 94 
as a virtual compartment linked to the maternal plasma compartment by a first-order process 95 
which does not modify the compartmental model in the mother. After delivery, this fetal 96 
compartment is disconnected, time is reset to zero and the neonate has his own elimination 97 
(Fig 1). Parameters of the model were the absorption rate constant (ka), maternal elimination 98 
clearance from the central compartment (CL), volume of the central maternal compartment 99 
(V1), maternal intercompartmental clearance (Q2), volume of the peripheral maternal 100 
compartment (V2), maternal to fetal rate constant (k1F), fetal to maternal rate constant (kF1) 101 
and neonate elimination rate constant (kFO). Since emtricitabine was orally administered, only 102 
ka, CL/F, V1/F, Q2/F, V2/F, k1F, kF1 and kFO were identifiable, where F is the unknown 103 
bioavailability. Analytical equations were used in a $PRED section in NONMEM to estimate 104 
these pharmacokinetic parameters. When FTC concentrations were below the LOQ, we set 105 
them to half of the LOQ. Several error models were investigated (i.e. multiplicative and 106 
additive error models) to describe residual variability. Exponential model was used for inter-107 
subject variability (ISV). Only significant ISVs on pharmacokinetic were kept. The effect of 108 
each patient covariate was systematically tested via generalized additive modeling on the 109 
basic model. Continuous covariates (CO), as bodyweight, gestational age, creatinine, height 110 
and body surface area were tested according to the following equation, using CL for example, 111 
CL
COβ
CL )
median(CO)
CO(θCL ×= , where  θCL is the typical value of clearance for a patient with 112 
the median covariate value and CLCOβ  is the estimated influential factor for the continuous 113 
covariate. When a covariate was missing, it was set to the median value from all the other 114 
women. Categorical covariates (CA =0 or 1) were tested according to   115 
CA)β(1θCL CLCACL ×+×=  for inducing effect or CA)β(1/θCL CLCACL ×+=  for inhibitory 116 
effect. The type of delivery (TD) was tested according to DEL)TDβ(1θCL CLTDCL ××+×= , 117 
where DEL = 1 before delivery and DEL = 0 after delivery. A covariate was kept if its effect 118 
was biologically plausible; it produced a minimum reduction of 6.63 in the objective function 119 
value (OFV) and a reduction in the variability of the pharmacokinetic parameter, assessed by 120 
the associated inter-subject variability. An intermediate model with all significant covariates 121 
was obtained. A backward elimination phase was finally performed by deleting each covariate 122 
from the intermediate model, to obtain the final model, using a likelihood ratio test.  123 
 124 
Evaluation and validation 125 
For evaluation of the goodness-of-fit, the following graphs were performed: observed and 126 
predicted concentrations versus time, observed concentrations vs population predictions, 127 
weighted residuals vs time and weighted residuals vs predictions. Similar graphs using 128 
individual predictive POSTHOC estimation were displayed. The diagnostic graphs were 129 
performed using RfN (S. Urien, RFN-831-20070911, 130 
https://sourceforge.net/project/showfiles.php?group_id=29501&package_id=140129&release131 
_id=538680) with the R program (8).  132 
Emtricitabine concentration profiles were simulated and compared with the observed data 133 
thanks to visual predictive check in order to validate the model. More precisely, the vector of 134 
pharmacokinetic parameters from 1000 patients was simulated using the final model. Each 135 
vector parameter was drawn in a log-normal distribution with a variance corresponding to the 136 
ISV previously estimated. A simulated residual error was added to each simulated 137 
concentration.  The simulations were performed using NONMEM. The 5th, 50th and 95th 138 
percentiles of the simulated concentrations at each time were then overlaid on the observed 139 
concentration data using the R program and a visual inspection was performed. 140 
 141 
Maternal concentrations after 400 mg FTC administration to the mother before delivery and 142 
placental transfer. 143 
After the 400 mg administration to each pregnant woman, FTC minimal (Cmin) and maximal 144 
(Cmax) plasma concentration and area under the concentration curve (AUC) were derived from 145 
the estimated individual pharmacokinetic parameters. Median values and ranges were 146 
calculated and compared to data from adults, in literature. At delivery cord (i.e. fetal) and 147 
maternal plasma concentrations were determined. The ratio between fetal and maternal 148 
concentrations was calculated and its variation as a function of the delay between drug uptake 149 
and delivery was followed. In order to better evaluate placental transfer, for a 400 mg dose 150 
administered to the mother, maternal and neonatal areas under the curve were estimated and 151 
the ratio between neonatal and maternal AUC was calculated.  152 
 153 
Determination of the optimal dosing scheme for the newborn. 154 
The optimal timing for FTC administration to the newborns was determined in order to obtain 155 
a similar exposure to that observed in adults, (i.e. ( ) =→ neonateshAUC 240  10.4 mg/L.h) and to 156 
guarantee newborn FTC concentration above 0.077 mg/L (i.e. residual adult concentration), 157 
before the administration to the neonate and as long as possible after administration to the 158 
neonate. The target minimal concentration of 0.077 mg/L corresponds to the mean minimal 159 
concentration for FTC 200 mg QD in adults from 3 previous studies (0.071 mg/L for Zhong et 160 
al. (18), 0.075 mg/L for Blum et al.(5) and 0.085 mg/L for Ramanathan et al. (15) study). The 161 
following hypotheses were necessary: neonate has same bioavailability and absorption rate as 162 
his mother and neonatal volume of distribution VF is proportional to maternal volume of 163 
distribution on a bodyweight (BW) basis: VF = (V1+V2)* BWneonate/BWMother. Neonatal AUC 164 
was calculated taking into account both neonatal administration and mother-to-fetus drug 165 
transfer. As adults receive 200 mg doses or 3 mg/kg, a 3 mg/kg administration was simulated 166 
and this dose was modified in order to obtain a neonatal hAUC 240−  close to 10.4 (median 167 
adults AUC after a 200 mg dose). Different administration schemes were simulated in the 168 
neonates: 1, 2, 3 mg/kg, 1 hour after birth and 2 mg/kg 12 hours after birth. 169 
 170 
   171 
Results 172 
Demographic data 173 
Data from the 38 enrolled women and 32 of their neonates were available for FTC 174 
pharmacokinetic evaluation. Table 1 summarizes patients’ characteristics. 175 
 176 
Population pharmacokinetics 177 
A total of 411 maternal, 37 cord blood concentrations and 66 neonatal concentrations were 178 
used for pharmacokinetic analysis. Four maternal residual FTC concentrations were excluded 179 
because they were seven to 20 times higher than the three other residual concentrations in the 180 
same patient. Seven FTC concentrations were lower than the LOQ, so they were set to half of 181 
the LOQ (1). The available data were not sufficient to estimate inter-subject variability for 182 
V1/F, Q2/F, V2/F, k1F and kF1 and fixing the variance of these random effects to zero had no 183 
influence on the objective function values (OFV). Variabilities were thus estimated: for ka, 184 
CL/F and kFO. All residual variabilities were best described by a proportional error model. 185 
The addition of a correlation between mother and cord residual variabilities, using a L2 item, 186 
(r= 0.80 (24%)) decreased OFV by 11.8 units. The effects of maternal bodyweight, serum 187 
creatinine, gestational age and type of delivery were tested on CL/F and the effects of 188 
neonatal bodyweight, height, body surface area and gestational age were tested on kFO, none 189 
of these effects was significant. 190 
Figure 2 displays FTC observed and predicted plasma concentrations as a function of time for 191 
the mother, the cord and the neonate. To better visualize neonatal concentrations, cord 192 
concentrations were reported on the graph at time zero. Table 2 summarizes the final 193 
population pharmacokinetic estimates. Final model performance was appreciated by 194 
comparing population predicted and individual predicted to observed plasma concentrations 195 
and population weighted residuals versus predicted concentrations and versus time for FTC 196 
(not shown).  197 
 198 
Validation 199 
Visual predictive check of the final population pharmacokinetic model (Fig 3) showed the 5th, 200 
50th and 95th predicted percentiles from the 1000 simulations and the observed concentrations 201 
of emtricitabine. The visual predictive checking confirmed that the average prediction 202 
matched the observed concentrations. The variability was reasonably estimated.  203 
 204 
Maternal concentrations  after 400 mg administration to the mother before delivery  205 
Table 3 summarizes the maternal Cmin, Cmax and AUC obtained after a 400 mg administration 206 
to the pregnant woman at the start of the labour, and values previously found after a 200 mg 207 
administration to adults, at steady state. In the present study, total elimination clearance was 208 
28 L/h for women at delivery, after a 400 mg dose whereas in previous studies, the mean 209 
value was 19.3 L/h in adults after a 200 mg dose. Total elimination clearance increased by 210 
45% in pregnant woman, on the day of delivery.  211 
 212 
Placental transfer 213 
Median delay between samples drawn before the first maternal FTC administration and 214 
delivery was 5.1 hours (min - max: 0.6 - 20 hours). At delivery, median predicted neonatal 215 
and maternal concentrations were respectively 0.72 mg/L (min – max: 0.05 - 1.19) and 1.16 216 
mg/L (min – max: 0.14 - 1.99). The median predicted ratio between cord and maternal 217 
concentrations at delivery was 76 % (min – max: 9 - 144), depending on the delay between 218 
maternal drug administration and delivery. This range of concentration ratio at delivery 219 
suggests that placental transfer depends on the delay between maternal drug intake and 220 
delivery and could not be given as a simple percentage. A more representative measure of 221 
placental transfer would be the ratio between neonatal and maternal FTC AUC for 24 hours. 222 
Figure 4 represented maternal and neonatal concentrations as a function of time when delivery 223 
occured 2, 6 or 12 hours after maternal drug intake. This figure (down) showed the neonatal-224 
to-maternal AUC ratio as a function of the delay between maternal administration and labour.   225 
 226 
Determination of the optimal timing for FTC administration to the newborns. 227 
As the median predicted neonatal concentration was relatively high at delivery (0.72 mg/L), 228 
with a 10.6 hours half life, this remained above 0.077 mg/L (minimal adult concentrations) 229 
for at least 3 half-lives, i.e. 31.8 hours after delivery. Table 4 summarizes neonatal minimal 230 
concentration before administration, AUC0→24h and the time during which neonatal 231 
concentration remained over 0.077 mg/L for 1, 2 or 3 mg/kg at 1 hour after birth and 2 mg/kg 232 
12 hours after birth. If emtricitabine was only administered to the mother, thanks to placental 233 
transfer, it would produce a neonatal AUC0→24h of 8.2 mg/L.h. Administering, as a single 234 
dose, 1 mg/kg of emtricitabine 1 hour after birth or 2 mg/kg 12 hours after birth would allow 235 
the neonate to obtain same exposition as adults. These results were obtained assuming a 236 
neonatal volume of distribution (VF) proportional to the maternal volume of distribution on a 237 
bodyweight basis (mean VF = (V1+V2)* BWneonate / BWMother ≈ (127+237)*2.8/60.3 ≈ 16.9 L). 238 
However, 1 mg/kg 1 hour after birth would produce an AUC0-24h  of 9.2 mg/L.h and a 239 
concentration above 0.077 mg/L during 34 h if VF was in reality twice higher than in the 240 
assumption. This dose would produce an AUC0-24h of 12.0 mg/L.h and a concentration above 241 
0.077 mg/L during 40.2 h if the true VF was twice lower than assumed. In both cases, even 242 
with a 100% error on neonatal volume of distribution, the AUC0-24h was close to 10.4 mg/L.h. 243 
 244 
 245 
Discussion 246 
In the present work, emtricitabine mother and child pharmacokinetics were satisfactorily 247 
described by the proposed compartmental model. The following observations support the 248 
validity of this model: 249 
Population predicted maternal, cord and neonatal concentrations were well correlated with 250 
observed concentrations. The population model was validated thanks to the visual predictive 251 
check method. 252 
In pregnant women, the AUC obtained from our population model was decreased (14.3 253 
mg/L.h for a 400 mg dose, i.e. 7.15 mg/L.h for a 200 mg) compared to non pregnant adult 254 
value (10.7 mg/L.h for a 200 mg dose). This is in agreement with the PATCG/IMPAACT 255 
P1026 study which reports, during the third trimester of pregnancy, a median AUC of 8.6 256 
mg/L.h for a 200 mg dose (3).   257 
As shown in table 3, despite a higher elimination clearance in pregnant women than in non 258 
pregnant adults, the 400 mg emtricitabine administration before delivery produces higher 259 
exposure than the 200 mg administration in others adults at steady state. Calculating 260 
emtricitabine clearance as a dose to AUC ratio, we found 28.0 L/h for pregnant women (our 261 
study) compared to 18.7 L/h (4, 18) and 20.4 L/h for adults (15). FTC clearance was increased 262 
by 37 or 50 %. FTC is primarily excreted by the kidney by both glomerular filtration and 263 
tubular secretion with 86% recovery of the dose achieved in urine, as described in the full 264 
prescribing information for Truvada® (http://www.gilead.com/pdf/truvada_pi.pdf). During 265 
pregnancy, renal plasma flow increases by 25 to 50% and glomerular filtration rate by 50% 266 
which should have enhanced emtricitabine elimination (13). The lowest FTC clearance 267 
increase in the PATCG/IMPAACT P1026 study (23.3 vs 28.0 L/h in our study) may be due 268 
the sampling time during pregnancy (third trimester vs the day of delivery in our study). None 269 
of the covariates tested had an effect on maternal absorption or elimination clearance. 270 
No data were reported on emtricitabine placental transfer. In this study, from one sample at 271 
delivery (at various times after drug administration) in each mother – cord pairs, we could 272 
draw maternal and cord concentrations curves as a function of the delay and estimate inter 273 
subject and residual variabilities. Placental transfer was estimated as fetal to maternal 274 
exposure ratio to the drug. We found a relatively constant ratio of 80% for a delivery 275 
occurring at least 4 hours after maternal drug administration. This transfer seems to be mainly 276 
due to a passive diffusion of the drug through the placenta. Data about active transport are 277 
missing.  278 
 279 
Cord concentrations were relatively high (0.72 mg/L) compared to the minimal adult 280 
concentrations previously reported (0.07 mg/L). This was due to both a good placental 281 
transfer of the drug and a higher exposure in mothers; with 400 mg of emtricitabine at 282 
delivery time, maternal exposure was higher than the exposure with 200 mg in non pregnant 283 
adults. So, even if women delivered a long time after drug intake, cord concentrations should 284 
remain over the adult minimal concentration. However re-administering 2 tablets of Truvada® 285 
to the mother after 12 hours of labour (if she did not delivered yet, as suggested for tenofovir, 286 
unpublished data) would produce reasonable emtricitabine cord concentrations (similar to 287 
cord concentrations of a neonate born 5 hours after maternal first drug intake). 288 
 289 
The emtricitabine median neonatal half life was 10.6 hours, in agreement with Blum study 290 
reporting half lives of 12.5 hours in neonates from birth to 21 days, 11.5 hours for 22 to 42 291 
days old infants and 11.8 hours for 43 to 90 days old children (5). Moreover these half-lives 292 
are comparable to children values (9.3 to 11.7 hours for the 2 – 17 years) (17) and adults 293 
values (10.5 h for Blum, 9.4h for Zhong and 8.3 h for Ramanathan) (4, 15, 18).  294 
As the model was validated thanks to the visual predictive check method, it was used 295 
to simulate the optimal dosage. For this, it was assumed that the child had the same absorption 296 
rate and bioavailability as the mother and its volume of distribution was proportional to the 297 
total maternal volume distribution on a bodyweight basis. Accordingly, in our model, the 298 
mean volume of distribution was 16.9 L for a children weighting 2.7 kg at birth, which is 299 
close to the volume of distribution of 14 L (t1/2=12.5 h and CL=13mL/min) found in the 18 300 
children from 0 to 21 days of Blum’s study (5). Moreover, even with a 100% error on 301 
neonatal volume of distribution, the AUC0-24h and the time during which the concentration 302 
was above 0.077 mg/L showed a less than 20% change. The optimal single neonatal dose was 303 
determined in order to obtain an exposure in neonates similar to the known exposure in adults 304 
(i.e. 10.4 mg/L.h) and concentrations above the residual adult concentration (=0.077 mg/L) 305 
before, and as long as possible after neonatal administration. Criteria were based on plasma 306 
emtricitabine concentrations although intracellular emtricitabine triphosphate concentrations 307 
would have been more appropriate to follow the pharmacologically active part of FTC. It was 308 
also supposed that the enzymes of phosphorylation were matures in the neonates (16). For 309 
practical reasons, we suggest that FTC should be administered to the neonate at the same time 310 
as tenofovir (unpublished data). As previously shown, tenofovir should be administered 311 
quickly after birth, i.e. one hour after delivery, so we simulated concentrations obtained with 312 
1, 2 or 3 mg/kg of emtricitabine given one hour after birth to the neonate. A 2 mg/kg FTC 313 
dose given 12 hours after birth was also simulated. Taking into account the high exposure of 314 
the fetus to the drug due to maternal administration (AUC0-24h =8.2 mg/L.h), only 1 mg/kg of 315 
emtricitabine was needed one hour after birth to reach an AUC0-24h of 10.1 mg/L.h. However 316 
if the neonate could only be administered FTC 12 hours after birth, the dose would increase to 317 
2 mg/kg. This dosage is recommended for a single administration following birth and not for 318 
repeated doses as in the Blum study (5). 319 
 In conclusion, the maternal 400 mg emtricitabine administration before delivery 320 
produces higher exposure than the 200 mg administration in others adults at steady state. 321 
Emtricitabine placental transfer, described by neonatal to maternal exposure ratio was around 322 
80%. Finally, neonates should receive FTC 1 mg/kg as soon as possible after birth or 2 mg/kg 323 
12 hours after birth to have concentrations comparable to those observed in adults. The 324 
second step of TEmAA trial will validate these recommendations.  325 
 326 
 327 
 328 
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Broulaye Kone, Suzanne Kouadio, Guy César Kouaho, Jeanne Eliam 
Kouakou,  Sidonie Ngatchou, Touré Pety, Zenica Seoue, Mamourou 
Kone 
• Phnom Penh: Laurence Borand, Pinn Chou, Kearena Chhim, Meng Ly 
Ek, Viseth Horm Srey, Seng Hout, Sethikar Im, Saroeum Keo, Vannith 
Lim, Sopheak Ngin, Vara Ouk, Vibol Ung , and the Magna and 
Maryknoll associations 
• Soweto : Gail Ashford, Promise Duma, Portia Duma, Sarita Lalsab, 
Shini Legote, Tshepiso Mabena, Joseph Makhura, Modise Maphutha, 
Selvan Naidoo, Mandisa Nyati 
- Scientific Board: Pr Bernard Koffi Ngoran (Abidjan, Côte d’Ivoire), Pr Koum 
Kanal (Phnom Penh, Cambodia), Pr Lynn Morris (Johannesburg, South Africa), 
Dr Séverine Blesson (ANRS, Paris, France), Dr Camille Aubron-Olivier (Gilead 
Sciences, Paris, France), Pr Gilles Peytavin (Paris, France), Pr Koen Van Rompay 
(Davis, California, USA), Dr Valériane Leroy (Bordeaux, France) 
- Independent Committee: Prs John Sullivan (Worcester, Massachusetts, USA), 
Philippe Lepage (Brussels, Belgium), Laurent Mandelbrot (Paris, France), Marie-
Louise Newell (London, UK), Anne-Marie Taburet (Paris, France) 
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Figures 
 
Figure 1 
Population pharmacokinetic model for the simultaneous prediction of emtricitabine 
concentrations in the mother, the cord (top) and the neonate (bottom). A 2-compartment 
model with first-order absorption and elimination best described maternal data. For cord 
concentrations, an “effect” compartment is modeled as a virtual compartment linked to the 
maternal plasma compartment by a first-order process. After delivery, the fetal compartment 
is disconnected and the neonate has his own elimination. F denotes for bioavailability, D the 
emtricitabine maternal dose, ka the absorption rate constant, CL the maternal elimination 
clearance from the central compartment, V1 the volume of the central maternal compartment, 
Q2 the maternal intercompartmental clearance, V2 the volume of the peripheral maternal 
compartment, k1F maternal-to-fetal rate constant, kF1 the fetal-to-maternal rate constant, kFO 
neonate elimination rate constant, VF the fetal volume of distribution, BWM the maternal 
bodyweight and BWFPA the sum of neonatal bodyweight, placenta and amniotic fluid weight. 
 
Figure 2 
Left: Observed (points) and population predicted (lines) maternal emtricitabine concentrations 
versus time. Right: Observed (points) and population predicted (lines) emtricitabine 
concentrations in cord blood (up) and neonatal plasma (bottom) versus time.  
 
Figure 3  
Evaluation of the final model: comparison between the 5th (dash line), 50th (full line) and 95th 
(dash line) percentile obtained from 1000 simulations and the observed data (points) for 
emtricitabine concentrations in mother (left), cord blood (middle) and neonate (right).  
 Figure 4 
Up: Population predicted emtricitabine concentrations in the mother (full line) and her 
neonate (dashed line; cord equation before delivery and neonatal equation after) versus time: 
for a 2 hours (left), 6 hours (middle) or 12 hours (right) delay between drug administration 
and delivery time. Down: Neonatal-to-maternal emtricitabine AUC ratio as a function of the 
delay between drug administration and delivery time.  
 
     
 
 
 
   
Table 1. Characteristics of the HIV-infected pregnant women (N=38) enrolled in the 
pharmacokinetic study of the TEmAA ANRS 12109 trial, Step 1  
 
Covariates Median (Min-Max) 
Maternal bodyweight at delivery (kg) 58.3 (46.5 – 88.1) 
Gestationnel age (weeks) 39 (33  – 42)  
Delivery : vaginal, caesarian section (n) 24 , 14 
Maternal creatinine clearance at enrolment (µmol/L) 42.2 (26 – 88) 
Neonatal bodyweight at birth (kg) 2.7 (2.3 – 3.6) 
Neonatal height at birth (cm) 48.5 (46 – 53) 
Body surface area at birth (m²) 0.20 (0.18 – 0.23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Population pharmacokinetic parameters of emtricitabine from the final model 
for HIV-infected pregnant women (N=38) after receiving 400 mg of emtricitabine at the 
start of the labour and for their neonates (N=32) enrolled in the TEmAA ANRS 12109 
trial, Step 1 
 
Structural model Statistical model 
Parameter Estimate (RSE %) Parameter Estimate (RSE %) 
ka (h-1) 0.54 (11) ωka (%) 61 (29) 
CL/F (L/h) 23.2 (4) ωCL/F     (%) 17 (34) 
V1/F (L) 127 (7) ωKF0   (%) 30 (35) 
Q/F (L/h) 6.04 (10) σ MOTHER (%) 45 (14) 
V2/F (L) 237 (15) σ CORD (%) 43 (24) 
k1F (h-1) 0.289 (13) σ NEONATE (%) 33 (27) 
kF1 (h-1) 0.383 (13)   
kF0 (h-1) 0.0653 (7)   
 
Key: RSE%, relative standard error (standard error of estimate / estimate*100); ka absorption 
rate constant, CL/F maternal apparent elimination clearance from the central compartment, 
V1/F apparent volume of distribution of the central maternal compartment, Q2/F apparent 
maternal intercompartmental clearance, V2/F apparent volume of distribution of the peripheral 
maternal compartment, k1F maternal-to-fetal rate constant, kF1 fetal-to-maternal rate constant 
and kF0 neonate elimination rate constant. σ residual variability estimates (CV of residual 
variability, %) and ω, interindividual variability estimates (CV of intersubject variability, %). 
Table 3. Maternal minimal, maximal concentrations (Cmin and Cmax) and area under de 
curves (AUC), derived from women’s individual pharmacokinetic estimates, after a 400 
mg FTC dose to the HIV-infected pregnant women (N=38) enrolled in the TEmAA 
ANRS 12109 trial, Step 1, compared to median adults values after a 200 mg FTC dose at 
steady state. 
 
  
 
Median 
TEMAA 
Pregnant, 400 mg 
Zhong et al. (18) 
Adults, 200 mg 
Blum et al. (4) 
Adults, 200 mg 
Ramanathan et 
al. (15) Adults, 
200 mg 
AUC (mg/L.h) 14.3  (11.0 – 19.0) 10.7 10.7 9.8 
Cmin (mg/L) 0.076  (0.039 – 0.174) 0.071 0.075 0.085 
Cmax (mg/L) 1.68  (0.82 – 2.13) 2.18 1.69 1.68 
Table 4. Neonatal parameters estimated for an administration 0, 1, 2 and 3 mg/kg 1 hour 
after birth and 2 mg/kg 12 hours after birth, TEmAA ANRS 12109 trial, Step 1 
 
Median 0 mg/kg 
1 mg/kg 
at 1h 
2 mg/kg 
at 1h 
3 mg/kg 
at 1h 
2 mg/kg     
at 12 h 
AUC0→24 (mg/L.h) 8.2 10.1 11.9 13.4 10.5 
Cmin (mg/L)  0.67 0.67 0.67 0.31 
T (C>0.077) (h)  36.6 40.2 42.8 33.9 
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